/ /

Clinical Pharmacology

ICER, VA join to work on drug value, price negotiationsAnalysts discuss how pharmacoeconomics will make a difference in treatment decisions.
New therapies show promise in treating diabetes
New therapies show promise in treating diabetesNew updates in insulin products, as well as non-pharma therapies are on the horizon for diabetes.
Large variety of multiple myeloma treatment options presents challengesThere now exist numerous treatment options for multiple myeloma but how best to sequence them is still under study
Insurer: No more prior auths for opioid addiction medsAs part of efforts to combat the opioid epidemic, Cigna removes prior authorization from medication-assisted treatment for opioid use disorder.
Copay assistance programs: Managed care pros and consDo copay assistance program offer a long-term solution for patients? Experts weigh in.
Three ways to rein in drug costs regardless of who becomes presidentIt’s time for stakeholders to cooperate in order to limit the wasted spending on prescription medications and chart a path to collectively improving value derivation.
PDMPS: An effective but underutilized resource for prescribersMCOs are going to have to step up their efforts to impact the growing opioid epidemic in this country.
Nearly half of BCBS members discontinue this RA drug after 1 yearAnalysis from Prime shows that improvements in persistency, adherence is key in RA treatments.
Biosimilars and interchangeable biologics: News to watchBiosimilars in the United States are slowly gaining traction, but widespread confusion and legal barriers remain.
Five specialty pharmaceutical trends to watchApprovals of specialty pharmaceuticals have far outpaced traditional drugs, and that trend will continue. But that’s not the only specialty medication trend that healthcare executives should have on their radar.